Results 151 to 160 of about 18,729 (264)

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.

New England Journal of Medicine, 1998
Henry Krum, Reuven Viskoper, Yves Lacourcière, Michael L. Budde, Vincent Charlon   +4 more
semanticscholar   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease. [PDF]

Diabetes Obes Metab
Smeijer JD, Gomez MF, Rossing P, Heerspink HJL.   +3 more
europepmc   +1 more source

Can Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for Pulmonary Arterial Hypertension? Description of a Real-Life Case Series. [PDF]

Diagnostics (Basel)
Damiani A, Lepri G, Bonomi F, Fiorentini E, Peretti S, Blagojevic J, Bellando Randone S, Guiducci S.   +7 more
europepmc   +1 more source

The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network. [PDF]

Transplant Direct
DuBrock HM, Jose A, Arendse S, Martin N, Studer S, Rosenberg D.   +5 more
europepmc   +1 more source

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. [PDF]

Drug Des Devel Ther, 2019
Sidharta PN, Melchior M, Kankam MK, Dingemanse J.   +3 more
europepmc   +1 more source

Endothelin and endothelin receptor antagonists in systemic rheumatic disease [PDF]

Arthritis & Rheumatism, 2003
openaire   +2 more sources

Dose‐Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects

Clinical pharmacology and therapy, 2009
J. Smolander, B. Vogt, M. Maillard, C. Zweiacker, T. Littke, T. Hengelage, Michel Burnier   +6 more
semanticscholar   +1 more source

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

Journal of the American College of Cardiology, 2003
N. Galiè, A. Hinderliter, A. Torbicki, T. Fourme, G. Simonneau, T. Pulido, N. Espinola-Zavaleta, G. Rocchi, A. Manes, R. Frantz, M. Kurzyna, S. Nagueh, R. Barst, R. Channick, K. Dujardin, A. Kronenberg, I. Leconte, M. Rainisio, L. Rubin   +18 more
semanticscholar   +1 more source

Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.

Rheumatology, 2010
V. Nguyen, K. Eisendle, I. Gruber, B. Hugl, D. Reider, N. Reider   +5 more
semanticscholar   +1 more source